Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$25.57 USD
-0.01 (-0.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $25.50 -0.07 (-0.27%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Price, Consensus and EPS Surprise
ANIK 25.57 -0.01(-0.04%)
Will ANIK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ANIK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANIK
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
ANIK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Other News for ANIK
Medicare Administrators looking to 'drastically shake up' wound care, says BTIG
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Anika Therapeutics: Strong Q4 Performance and Upbeat FY2024 Outlook Justify Buy Rating and Raised Price Target
Anika Therapeutics price target raised by $8 at Barrington, here's why